Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study

February 1, 2024 updated by: VA Office of Research and Development

CSP #566 - Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study

This is a research study examining health effects of the Iraq War, especially those effects involving mental health. This study is a follow-up to the Neurocognition Deployment Health Study (NDHS), also called "Prospective Assessment of Neurocognition in Future Gulf-deployed and Gulf-nondeployed Military Personnel: A Pilot Study." The specific purpose of this research study is to find out more about the longer lasting effects of war on mood and stress symptoms, thinking and reaction skills, and different aspects of day to day life, such as work and daily activities. Survey and test results from previous participation in the NDHS will be compared to the new information that will be obtained from participants as part of this study. The investigators expect that a total of about 817 military personnel and military Veterans will participate in the study. There are two parts to this study: (1) mail/internet/phone survey and (2) in-person assessment. The investigators will invite all NDHS participants who deployed to Iraq to participate in the survey component. The survey component of the study involves being interviewed by phone about mood and stress symptoms and head injuries and completing written survey questions by either mail or on the internet that address basic personal history (such as age, military status, gender, combat injury history), mood, stress symptoms, and stressful experiences. The phone interview will take about 2 to 2.5 hours to complete. The questionnaire part will take about 20 to 30 minutes to complete, and can be completed either by mailing back completed questionnaires or by internet using a private, individual log-in/password combination. The investigators will invite approximately 200 selected at random from the larger group of survey responders to take part in the in-person assessment. The in-person assessment involves taking a small subset of neuropsychological tasks. The tasks will be given on a computer or using paper and pencil. Participants will also be asked to complete questionnaires about work, daily activities, and health history, as well as basic health measures such as height, weight, blood pressure, heart rate, and waist size. Potential participants will be given the option of completing the in-person assessment at one of the two study sites (Seattle or Boston), or in a private setting in their community (e.g., a hotel small conference room). Altogether, this part of the study will take about 120 minutes to 140 minutes to complete.

Study Overview

Status

Active, not recruiting

Detailed Description

As of August 2007, approximately 1.5 million U.S. service members had been deployed to either Iraq (Operation Iraqi Freedom, OIF) or Afghanistan (Operating Enduring Freedom, OEF). The sacrifices of these service members include >3500 fatalities and >35,000 injuries resulting in medical air transports. Medical sequelae, such as those involving traumatic amputations and traumatic brain injury, have been common. Contemporary military operations have also been linked to significant adverse mental health consequences. In particular, recent evidence suggests that both overt psychiatric symptoms and other functionally-relevant problems, such as attention and memory impairment, occur. These adverse mental health consequences, already observed in the immediate aftermath of war, could constitute a significant public health problem if prevalent and persistent.

In this context, Cooperative Studies Program (CSP) study #566 proposes an observational cohort design to examine war-related mental health dysfunction beyond the immediate aftermath of war. The proposed work builds on a unique data set available from the Neurocognition Deployment Health Study (NDHS), an interagency collaboration between the Department of Defense (DoD) and the Department of Veterans Affairs (VA). Initiated in April 2003, with an initial enrollment of 1595 participants, the NDHS has focused on short-term mental health outcomes of OIF deployment. To date, the NDHS is the only deployment health study of U.S. troops that includes both prospectively-gathered pre-deployment (baseline) and post-deployment (within 90 days after return from the war) data, as well as objective, performance-based measures of mental functioning.

The proposed work would collect new "long-term follow-up" data 3 to 5 years after NDHS participants returned from their initial deployment to Iraq. The newly acquired data from the proposed work will be analyzed with data available from the previous waves of the NDHS. The two primary objectives of CSP #566 are to: (1) determine the prevalence and course of posttraumatic stress disorder (PTSD) among Iraq War Veterans 3-5 years following return from their Iraq War deployment; and (2) assess the persistence of previously observed neuropsychological changes (in attention, verbal learning, visual memory, and reaction time) following war-zone participation and their relationships to the subsequent development of PTSD as the end-point. The second primary objective also evaluates traumatic brain injury (TBI) as a possible neural risk factor for PTSD.

The two secondary objectives are to: (1) examine the association of risk and resilience factors, including the impact of war zone stressors, with the outcomes of PTSD, major depressive disorder (MDD), and panic disorder; and (2) determine whether changes in PTSD symptoms or neuropsychological function are associated with subsequent day-to-day functioning, including health-related functional activities and occupational functioning.

The proposed study includes two hierarchical participant sampling frames: (1) a "full sample" (N=817) for examination of PTSD and related outcomes; and (2) a "neuropsychological subsample" (N=200) for examination of neuropsychological and functional outcomes. Both samples are drawn from the anticipated 1149 participants from the original NDHS cohort who deployed to Iraq and consented to be contacted for future research. The "full sample" component includes clinician-administered structured psychiatric phone interviews to determine clinically significant cases of PTSD, major depressive disorder, and panic disorder; a mail questionnaire survey will provide assessment of posttraumatic stress (PTS) symptom severity. The "neuropsychological sample" component includes in-person performance-based assessment of neuropsychological outcomes, shown previously to be affected by deployment to Iraq. In addition, participants in the neuropsychological sample will complete questionnaires relevant to health-related functional impact and occupational functioning.

The planned duration of the study is 5.5 years, including a 6 month start-up period, 42 months to locate, contact, and complete assessments on participants, 6 months to lock and close the database, and 12 months to complete the primary and secondary analyses. The attributes of the established study population, in combination with the scope of the proposed work, offer a unique opportunity to answer scientific questions with direct relevance to healthcare policy for returning OIF Veterans. Specifically, this study can 1) identify quantifiable and objective measures associated with subsequent outcome and functioning, 2) determine early potentially modifiable factors that may be used to promote resilience, 3) optimize treatment "windows," and 4) help project future resource allocation based on the frequency and impact of the mental health problems identified.

Study Type

Observational

Enrollment (Actual)

817

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Connecticut
      • West Haven, Connecticut, United States, 06516
        • CERC (VISN1, West Haven, CT)
    • Massachusetts
      • Boston, Massachusetts, United States, 02130
        • VA Medical Center, Jamaica Plain Campus
      • Boston, Massachusetts, United States, 02130-4817
        • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
    • Washington
      • Seattle, Washington, United States, 98108
        • VA Puget Sound Health Care System, Seattle

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Surviving members of the NDHS cohort of 1595 participants

Description

Inclusion Criteria:

  • Deployment to Iraq with completed NDHS baseline assessments

Exclusion Criteria:

  • non-deployed,
  • sensory-motor or cognitive loss sufficiently profound to permit meaningful participation in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Neurocognition Deployment Health Study (NDHS) participants
Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTSD diagnosis (current CAPS dx); PTSD threshold (PCL derived screening estimate)
Time Frame: 5 years
  1. PTSD dx (current CAPS dx at T3)
  2. PTSD threshold dx (PCL-derived screening estimate) for T3 vs. T1 comparison
  3. Trajectory patterns of PTSD threshold dx* (PCL-derived screening estimate) at T1, T2, and/or T3:

    • never (T1-,T2-,T3-)
    • persistent (T1-,T2+,T3+)
    • recovered (T1-,T2+,T3-)
    • late onset (T1-,T2-,T3+)
    • all others, e.g., pre- existing (T1+,T2+,T3+)

[* +/- regarding PTSD threshold at time T1,2,3]

5 years
Neuropsych performance
Time Frame: 5 years
  • Neuropysch performance (T1 v. T2 v. T3)
  • PTSD diagnosis (CAPS dx); PTS symptom severity (PCL summary scores) (T3)
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association of early/deploy/post-deploy stress exposures and PTSD, MDD, panic
Time Frame: 5 years
  • PTSD (CAPS current dx) (T3)
  • Mood Disorders, Panic Disorder, Agoraphobia, and Generalized Anxiety Disorders (MINI) (T3)
  • PTS symptom severity (PCL summary scores) (T3)
  • Depression symptom severity (CES-D summary scores) (T3)
  • Anxiety symptoms severity (DASS anxiety subscale) (T3)
5 years
Association from pre-deploy to long-term follow-up (T3)
Time Frame: 5 years
  • Employment (T3)
  • Absenteeism (HPQ) (T3)
  • Work performance (HPQ) (T3)
  • Health-related functioning (SFv12) (T3)
  • Cognitive-related functioning (MOS CF) (T3)
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jennifer J Vasterling, PhD, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 31, 2010

Primary Completion (Actual)

July 10, 2014

Study Completion (Estimated)

September 30, 2025

Study Registration Dates

First Submitted

September 5, 2008

First Submitted That Met QC Criteria

September 8, 2008

First Posted (Estimated)

September 9, 2008

Study Record Updates

Last Update Posted (Estimated)

February 5, 2024

Last Update Submitted That Met QC Criteria

February 1, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress Disorders, Post-Traumatic

3
Subscribe